One-Time gene therapy could change pompe disease treatment

NCT ID NCT07282847

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a single intravenous dose of a gene therapy called AB-1009 in 12 adults with late-onset Pompe disease. Participants must have been on enzyme replacement therapy for at least 6 months. The main goal is to check safety and side effects, while also seeing if the treatment helps control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barrow Neurological Institute

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85013, United States

  • Duke University

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • NYU Langone

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Stanford Neuroscience Health Center

    NOT_YET_RECRUITING

    Palo Alto, California, 94304, United States

  • University of California, Irvine (UCI)

    RECRUITING

    Irvine, California, 92697, United States

  • University of Pittsburgh Medical Center (UPMC)

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Texas Southwest Medical Center

    RECRUITING

    Dallas, Texas, 75235, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Virginia Commonwealth University (VCU)

    NOT_YET_RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.